高级检索
当前位置: 首页 > 详情页

Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 自然指数

机构: [1]National Cancer Center, State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China [2]Hunan Cancer Hospital, Changsha, People’s Republic of China [3]First Affiliated Hospital, Jilin University, Changchun, People’s Republic of China [4]The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People’s Republic of China [5]Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China [6]Cancer Center of Hebei Province and The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China [7]Peking University Cancer Hospital and Institute, Beijing, People’s Republic of China [8]Tongji Hospital, Huazhong University of Science and Technology, Wuhan, People’s Republic of China [9]Jiangsu Cancer Hospital, Nanjing, People’s Republic of China [10]Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China [11]Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China [12]Jiangsu Hengrui Medicine, Shanghai, People’s Republic of China
出处:
ISSN:

摘要:
PURPOSEPyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in an open-label, multicenter, randomized phase II study.PATIENTS AND METHODSChinese patients with HER2-positive relapsed or metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400 mg pyrotinib or lapatinib 1,250 mg orally once per day for 21-day cycles in combination with capecitabine (1,000 mg/m(2) orally twice per day on days 1 to 14). The primary end point was investigator-assessed overall response rate per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.RESULTSBetween May 29, 2015, and March 15, 2016, 128 eligible patients were randomly assigned to the pyrotinib (n = 65) or lapatinib (n = 63) treatment groups. The overall response rate was 78.5% (95% CI, 68.5% to 88.5%) with pyrotinib and 57.1% (95% CI, 44.9% to 69.4%) with lapatinib (treatment difference, 21.3%; 95% CI, 4.0% to 38.7%; P = .01). The median progression-free survival was 18.1 months (95% CI, 13.9 months to not reached) with pyrotinib and 7.0 months (95% CI, 5.6 to 9.8 months) with lapatinib (adjusted hazard ratio, 0.36; 95% CI, 0.23 to 0.58; P < .001). The most frequent grade 3 to 4 adverse events were hand-foot syndrome in 16 of 65 patients (24.6%) in the pyrotinib group versus 13 of 63 (20.6%) in the lapatinib group; diarrhea in 10 patients (15.4%) versus three patients (4.8%), respectively; and decreased neutrophil count in six patients (9.2%) versus two patients (3.2%), respectively.CONCLUSIONIn women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinib plus capecitabine in this randomized phase II trial.

基金:

基金编号: 2017-12M-3-004 CAMS-12M-1-010 2015ZX0910100703 2015ZX0910100704

语种:
高被引:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2019]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区:
出版当年[2019]版:
Q1 ONCOLOGY
最新[2024]版:
Q1 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]National Cancer Center, State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
通讯作者:
通讯机构: [*1]Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan South Ln, Chaoyang District, Beijing, 100021, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号